Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin
 D.
During a 4-week washout period, participants stopped taking cinacalcet or other vitamin D
 receptor activators (VDRAs). (Participants who were naive to cinacalcet or VDRAs did not have
 to wash out). At randomization, participants entered a 28-week open-label treatment period,
 during which they received either cinacalcet or paricalcitol. Participants who were assigned
 to receive paricalcitol were dosed according to the approved label in their respective
 geographic regions (i.e., IV at sites in the US and Russia and oral at sites in Europe).
 Supplemental cinacalcet was administered to participants in the paricalcitol arms who
 developed hypercalcemia (defined as >= 10.5 mg/dL). The evaluation period was from Weeks 21
 to 28.
Inclusion Criteria

 1. Male or female patients >= 18 years old.

 2. Patient was diagnosed with Stage 5 chronic kidney disease (CKD) and had been receiving
 intravenous (IV) or oral vitamin D receptor activators (VDRAs) or cinacalcet during
 the 8 weeks prior to the screening period or naïve patients who had not received VDRA
 or cinacalcet within 8 weeks of screening.

 3. Patient was on maintenance HD (hemodialysis) 3 times weekly (TIW) for at least 3
 months prior to screening and was expected to remain on HD for the duration of the
 study.

 4. For entry into the Pre-Treatment Washout Period (for patients who were not naïve to
 VDRAs and cinacalcet), the patient had to have screening laboratory values of:

 -  iPTH level 130 to 700 pg/mL

 -  Serum Total Alkaline Phosphatase level >= 40 U/L

 -  Calcium level <= 10.0 mg/dL (2.49 mmol/L)

 -  Calcium-phosphorus product (CaxP) <= 75 mg2/dL2 (US) and <= 70 mg2/dL2 (non-US)

 Exclusion Criteria

 1. Patient had a history of parathyroidectomy.

 2. Patient had a current malignancy (with the exception of basal or squamous cell
 carcinoma of the skin), or clinically significant liver disease, in the opinion of the
 investigator.

 3. Use of known inhibitors (i.e., ketoconazole) or inducers (i.e., carbamazepine) of
 cytochrome P450 (including grapefruit and/or grapefruit juice) 3A (CYP3A) or drugs
 metabolized by cytochrome P450 2D6 (CYP2D6) (e.g., flecainide, vinblastine,
 thioridazine, and most tricyclic antidepressants) within 2 weeks prior to study drug
 administration. Commonly used beta blockers such as metoprolol and carvedilol are
 allowed but are metabolized by CYP2D6; thus, an adjustment to a lower dose may have
 been required.

 4. Patient was known to be human immunodeficiency (HIV) positive.